Leerink Partnrs Has Negative View of Belite Bio Q2 Earnings

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Stock analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for Belite Bio in a note issued to investors on Monday, July 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($0.46) per share for the quarter, down from their prior estimate of ($0.35). The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio's Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $7.05 EPS.

A number of other brokerages also recently issued reports on BLTE. Benchmark reissued a "buy" rating and set a $80.00 price objective on shares of Belite Bio in a research report on Wednesday, March 26th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a research report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Belite Bio in a research report on Thursday, July 3rd. Finally, Wall Street Zen lowered Belite Bio from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, Belite Bio has a consensus rating of "Moderate Buy" and a consensus price target of $96.67.

Belite Bio Stock Up 1.3%

Shares of NASDAQ BLTE traded up $0.81 during midday trading on Thursday, hitting $62.84. The stock had a trading volume of 162,352 shares, compared to its average volume of 46,380. The company has a market cap of $2.00 billion, a P/E ratio of -46.16 and a beta of -1.50. Belite Bio has a 52 week low of $43.70 and a 52 week high of $86.53. The business's 50 day moving average is $61.70 and its 200-day moving average is $60.47.

Hedge Funds Weigh In On Belite Bio

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its position in shares of Belite Bio by 43.3% during the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock worth $122,000 after purchasing an additional 559 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Belite Bio in the 4th quarter valued at $155,000. XTX Topco Ltd increased its position in shares of Belite Bio by 30.9% in the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after acquiring an additional 1,668 shares during the period. JPMorgan Chase & Co. increased its position in shares of Belite Bio by 130.3% in the 4th quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company's stock valued at $924,000 after acquiring an additional 8,280 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock valued at $1,157,000 after acquiring an additional 4,891 shares during the period. 0.53% of the stock is owned by institutional investors and hedge funds.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.